ChemoCentryx, Inc. (CCXI)

Market Cap	3.72B
Revenue (ttm)	37.28M
Net Income (ttm)	-133.09M
Shares Out	71.92M
EPS (ttm)	-2.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	735,267
Open	51.67
Previous Close	51.66
Day's Range	51.66 - 51.79
52-Week Range	14.95 - 51.85
Beta	1.24
Analysts	Hold
Price Target	53.04 (+2.7%)
Earnings Date	Nov 7, 2022

About CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy...

• Industry: Biotechnology
• IPO Date: Feb 8, 2012
• CEO: Thomas Schall
• Employees: 178
• Stock Exchange: NASDAQ
• Ticker Symbol: CCXI

Full Company Profile

Financial Performance

In 2021, ChemoCentryx's revenue was $32.22 million, a decrease of -50.34% compared to the previous year's $64.89 million. Losses were -$131.76 million, 138.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CCXI stock is "Hold." The 12-month stock price forecast is 53.04, which is an increase of 2.67% from the latest price.

Price Target

$53.04

(2.67% upside)

Analyst Consensus: Hold

Stock Forecasts